Suppr超能文献

雌激素与 Stat3/NF-κB 驱动的肺癌免疫调节之间的相互作用。

Interplay between estrogen and Stat3/NF-κB-driven immunomodulation in lung cancer.

机构信息

Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Carcinogenesis. 2020 Nov 13;41(11):1529-1542. doi: 10.1093/carcin/bgaa064.

Abstract

K-ras mutant lung adenocarcinoma (LUAD) is the most common type of lung cancer, displays abysmal prognosis and is tightly linked to tumor-promoting inflammation, which is increasingly recognized as a target for therapeutic intervention. We have recently shown a gender-specific role for epithelial Stat3 signaling in the pathogenesis of K-ras mutant LUAD. The absence of epithelial Stat3 in male K-ras mutant mice (LR/Stat3Δ/Δ mice) promoted tumorigenesis and induced a nuclear factor-kappaB (NF-κB)-driven pro-tumor immune response while reducing tumorigenesis and enhancing anti-tumor immunity in female counterparts. In the present study, we manipulated estrogen and NF-κB signaling to study the mechanisms underlying this intriguing gender-disparity. In LR/Stat3Δ/Δ females, estrogen deprivation by bilateral oophorectomy resulted in higher tumor burden, an induction of NF-κB-driven immunosuppressive response, and reduced anti-tumor cytotoxicity, whereas estrogen replacement reversed these changes. On the other hand, exogenous estrogen in males successfully inhibited tumorigenesis, attenuated NF-κB-driven immunosuppression and boosted anti-tumor immunity. Mechanistically, genetic targeting of epithelial NF-κB activity resulted in reduced tumorigenesis and enhanced the anti-tumor immune response in LR/Stat3Δ/Δ males, but not females. Our data suggest that estrogen exerts a context-specific anti-tumor effect through inhibiting NF-κB-driven tumor-promoting inflammation and provide insights into developing novel personalized therapeutic strategies for K-ras mutant LUAD.

摘要

KRAS 突变型肺腺癌(LUAD)是最常见的肺癌类型,预后极差,与促进肿瘤发生的炎症密切相关,后者正日益被认为是治疗干预的靶点。我们最近发现,上皮细胞 STAT3 信号在 KRAS 突变型 LUAD 的发病机制中具有性别特异性作用。在雄性 KRAS 突变型小鼠(LR/Stat3Δ/Δ 小鼠)中缺失上皮细胞 STAT3 可促进肿瘤发生,并诱导核因子-κB(NF-κB)驱动的促肿瘤免疫反应,同时减少雌性对应物的肿瘤发生并增强抗肿瘤免疫。在本研究中,我们操纵雌激素和 NF-κB 信号转导来研究这种有趣的性别差异的机制。在 LR/Stat3Δ/Δ 雌性小鼠中,双侧卵巢切除术导致雌激素剥夺导致肿瘤负担增加、NF-κB 驱动的免疫抑制反应诱导和抗肿瘤细胞毒性降低,而雌激素替代则逆转了这些变化。另一方面,雄性中的外源性雌激素成功抑制了肿瘤发生,减轻了 NF-κB 驱动的免疫抑制作用,并增强了抗肿瘤免疫。从机制上讲,上皮细胞 NF-κB 活性的基因靶向导致 LR/Stat3Δ/Δ 雄性中的肿瘤发生减少和抗肿瘤免疫反应增强,但在雌性中则没有。我们的数据表明,雌激素通过抑制 NF-κB 驱动的肿瘤促进炎症发挥特定于背景的抗肿瘤作用,并为开发 KRAS 突变型 LUAD 的新型个性化治疗策略提供了思路。

相似文献

引用本文的文献

4
Sex-specific outcomes in cancer therapy: the central role of hormones.癌症治疗中的性别特异性结果:激素的核心作用。
Front Med Technol. 2024 Feb 1;6:1320690. doi: 10.3389/fmedt.2024.1320690. eCollection 2024.
9
Pulmonary Inflammation and KRAS Mutation in Lung Cancer.肺癌中的肺部炎症和 KRAS 突变。
Adv Exp Med Biol. 2021;1303:71-87. doi: 10.1007/978-3-030-63046-1_5.

本文引用的文献

5
Cancer statistics, 2019.癌症统计数据,2019 年。
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
10
Estrogen, Estrogen Receptor and Lung Cancer.雌激素、雌激素受体与肺癌
Int J Mol Sci. 2017 Aug 5;18(8):1713. doi: 10.3390/ijms18081713.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验